Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
High Dose Carfilzomib for Newly Diagnosed Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT02937571
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q
- Conditions
- Interventions
- First Posted Date
- 2016-10-10
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Associazione Qol-one
- Target Recruit Count
- 2
- Registration Number
- NCT02928419
- Locations
- 🇫🇷
CHU d'Angers, Angers, France
🇫🇷Centre Henri Mondor, Creteil, France
🇫🇷Centre de Marseille, Marseille, France
Comparing Ropivacaine and Bupivacaine in DTFNB Anesthesia in Patients Undergoing Phacoemulsification
- Conditions
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Government Medical College, Haldwani
- Target Recruit Count
- 100
- Registration Number
- NCT02925832
- Locations
- 🇮🇳
Government medical college, Haldwani, Uttarakhand, India
Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
- Conditions
- Interventions
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 21
- Registration Number
- NCT02921893
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 7
- Registration Number
- NCT02918331
A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 34
- Registration Number
- NCT02917941
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 55
- Registration Number
- NCT02916771
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT02911142
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 12
- Registration Number
- NCT02906332
- Locations
- 🇺🇸
John Theurer Cancer Center-Hackensack Meridian Health, Hackensack, New Jersey, United States
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 8
- Registration Number
- NCT02903381
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.